U.S. Markets closed

  • S&P 500

    4,228.48
    -55.26 (-1.29%)
     

  • Dow 30

    33,706.74
    -292.30 (-0.86%)
     

  • Nasdaq

    12,705.21
    -260.08 (-2.01%)
     

  • Russell 2000

    1,957.35
    -43.38 (-2.17%)
     

  • Crude Oil

    89.91
    -0.59 (-0.65%)
     

  • Gold

    1,760.30
    -10.90 (-0.62%)
     

  • Silver

    18.97
    -0.50 (-2.56%)
     

  • EUR/USD

    1.0044
    -0.0048 (-0.4721%)
     

  • 10-Yr Bond

    2.9890
    +0.1090 (+3.78%)
     

  • Vix

    20.60
    +1.04 (+5.32%)
     

  • GBP/USD

    1.1823
    -0.0109 (-0.9163%)
     

  • USD/JPY

    136.9300
    +1.0680 (+0.7861%)
     

  • BTC-USD

    21,125.79
    -1,678.54 (-7.36%)
     

  • CMC Crypto 200

    504.88
    -36.72 (-6.78%)
     

  • FTSE 100

    7,550.37
    +8.52 (+0.11%)
     

  • Nikkei 225

    28,930.33
    -11.77 (-0.04%)
     

On verge of moving into a bigger headquarters, here's how Treace Medical is pursuing growth

Julian Hast
·4 min read
On verge of moving into a bigger headquarters, here's how Treace Medical is pursuing growth
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TMCI

Since it was founded in 2014, Treace Medical Concepts, Inc. (NASDAQ: TMCI) has been pursuing dominance in a niche market that it believes is untapped and underserved. “Some companies grow by offering everything to everyone,” said Mark Hair, chief financial officer of the Ponte Vedra Beach-based orthopedic medical device company. “We are really, truly focused on the bunion and concomitant issues in the foot.”

Continue reading

Recommended Stories

  • Crypto prices slide as FDIC issues cease and desist letters to crypto companies

    Markets correspondent Jared Blikre takes a look at the declining pricing for cryptocurrencies bitcoin and ethereum as the FDIC issue letters to five crypto companies.

  • Billionaire George Soros Pours Money Into These 2 ‘Strong Buy’ Stocks

    In the world of stock legends, George Soros stands out. While his political activities have been a lightning rod for controversy, no one can doubt his financial acumen. After all, he’s the ‘man who broke the Bank of England,’ and made a billion dollars in one day when he shorted the Pound Sterling back in 1992. His hedge fund, Soros Fund Management, showed three decades of sustained gains, averaging 30% annual returns through the year 2000. During this time, and today in the management of his pe

  • Why GigaCloud Stock Soared Higher on Friday

    The stock rose as much as 272% but is up about 175% as of 1:25 p.m. ET. The tech stock's gain came on the day of its initial public offering (IPO). Given the way the stock is soaring, the market apparently thinks the IPO was underpriced.

  • Stocks moving in after hours: Bed Bath & Beyond, Apple, Tesla, Walmart, Target

    Yahoo Finance Live co-anchor Seana Smith looks at several trending stocks moving in after-hours trading.

  • US Mortgage Lenders Are Starting to Go Broke

    (Bloomberg) -- The US mortgage industry is seeing its first lenders go out of business after a sudden spike in lending rates, and the wave of failures that’s coming could be the worst since the housing bubble burst about 15 years ago. Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeMueller Memo Advising Barr on Trump Findings Is Ordered ReleasedStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targ

  • This investor made $110 million from trading Bed Bath & Beyond — and he’s a 20-year-old student

    A 20-year-old USC student has made a $110 million profit from trading meme stock favorite Bed Bath & Beyond, following a frenzy in Wednesday’s trading session.

  • Why StoneCo Stock Fell Hard Today

    Shares of StoneCo (NASDAQ: STNE), a cloud-based technology platform, plummeted Friday morning after the company reported its second-quarter results, which disappointed investors, and announced yet another shift to its management team. The company reported non-GAAP (adjusted) earnings of 0.25 Brazilian reals (equivalent to $0.05), which was an increase from a loss of 0.48 reals in the year-ago quarter, but was below Wall Street's consensus estimate of about 0.57 reals, or $0.11 per share. StoneCo's revenue in the quarter was 2.3 billion reals (about $442 million), 5% higher than the company's guidance, and up 275% from the year-ago quarter.

  • How a 20-year-old USC student netted $110m from a Bed Bath & Beyond stock dump at exactly the right time

    Jake Freeman cashed out his 6% stake in the meme stock after it exploded on Tuesday.

  • China sentences tycoon Xiao Jianhua to 13 years, fines his company $8.1 billion

    BEIJING (Reuters) -A Shanghai court on Friday sentenced Chinese-Canadian billionaire Xiao Jianhua, not seen in public since 2017, to 13 years in jail and fined his Tomorrow Holdings conglomerate 55.03 billion yuan ($8.1 billion), a record in China. Xiao and Tomorrow Holdings were charged with illegally siphoning away public deposits, betraying the use of entrusted property, and the illegal use of funds and bribery, the Shanghai First Intermediate Court said. China-born Xiao, known to have links to China's Communist Party elite, was last seen whisked away in a wheelchair from a luxury Hong Kong hotel in the early hours with his head covered, a source close to the tycoon told Reuters at the time.

  • GM stock is about to dust Tesla stock, analyst says

    Back up the EV on shares of General Motors, says this one analyst.

  • I’m 65 and want to retire in 6 months. I have a $125K annuity, plus $100K of money that I’m not sure what to do with. Should I get professional help?

    Question: I had $225,000 in my 401(k) and then I rolled over $125,000 to an annuity at 7%, as I wanted income. Should I hire a financial adviser to help? Answer: Congrats on your impending retirement — and know that it’s totally normal to feel like now may be the time to hire a financial adviser.

  • How The Rich Avoid Paying Taxes on Savings Accounts

    If you keep money in a regular savings account you will generally owe federal income taxes on the interest that is earned. You'll pay taxes at your regular rate the year interest is earned, whether or not you withdraw from … Continue reading → The post How to Avoid Tax on a Savings Account appeared first on SmartAsset Blog.

  • With Bear Market Scars, These 37 Stocks Expect 111% To 762% Growth

    Oil stocks and chemicals dominate this list of today's fastest-growing stocks, all eyeing 111%-762% EPS gains this year.

  • 7 REITs Paying Huge Dividends

    One of the big reasons for investing in real estate investment trusts (REITs) is the kind of dividends many pay. While Treasury bonds are just beginning to catch up with inflation, some REITs offer better yields as long as investors are willing to accept the risks attached to owning them. Here are seven REITs with better-than-average, hard-to-ignore dividend yields: AGNC Investment Corp. (NASDAQ: AGNC) is paying 11.36% at a price of $12.57. The Bethesda, Maryland-based company specializes in res

  • Axsome’s depression drug receives FDA approval

    Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.

  • Missed BBBY? 10 'Meme Stocks' Are Next Gold Mines, Analysts Say

    Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.

  • Why I Bought the Stock of This Hated Company

    It's no wonder Altria's (NYSE: MO) stock has lost more than a fifth of its value in just a couple of months. Marketing partner Philip Morris International (NYSE: PM) is getting cold feet on working with Altria to sell its IQOS heated tobacco device while also just acquiring the leading competitor to Altria's own smokeless tobacco products. At the same time, the federal government all but obliterated Altria's $13 billion investment in Juul Labs, the one-time electronic-cigarette leader.

  • Axsome Wins A 60-Year First In Depression; And Shares Catapult 40%

    The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.

  • Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?

    The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood. Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high. Related: Aeglea BioTherapeutics Shares

  • Gasoline Prices Are Down, But There's a Big Threat Looming

    Prices at the pump have fallen again, but the summer decline is mostly over, according to industry watchers.